10 Best Medical Devices for February 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The healthcare sector, particularly medical devices and diagnostics, shows resilience amid market volatility, with steady revenue growth and strong free cash flow generation across leaders. Value Sense selected these 10 top healthcare stock picks using proprietary machine learning-driven analysis, focusing on companies with Quality ratings above 6.0, robust ROIC, healthy margins, and intrinsic values suggesting undervaluation. Criteria emphasize undervalued stocks trading below estimated intrinsic worth, positive revenue growth, and balanced debt levels, drawn exclusively from Value Sense's automated fundamental screening for long-term potential in medical devices stock picks and broader healthcare.
Featured Stock Analysis
Stock #1: Amazon.com, Inc. (AMZN)
| Metric | Value |
|---|---|
| Market Cap | $2,571.2B |
| Quality Rating | 6.1 |
| Intrinsic Value | $164.8 |
| 1Y Return | 2.0% |
| Revenue | $691.3B |
| Free Cash Flow | $10.6B |
| Revenue Growth | 11.5% |
| FCF margin | 1.5% |
| Gross margin | 50.5% |
| ROIC | 15.4% |
| Total Debt to Equity | 36.6% |
Investment Thesis
Amazon.com, Inc. (AMZN) stands out with a massive Market Cap of $2,571.2B and Revenue of $691.3B, driven by diversified operations including AWS cloud services. Despite a modest 1Y Return of 2.0%, its Quality rating of 6.1 reflects solid fundamentals like 11.5% Revenue growth, 15.4% ROIC, and 50.5% Gross margin. The Intrinsic value of $164.8 indicates potential undervaluation, supported by $10.6B Free Cash Flow even at a low 1.5% FCF margin, positioning AMZN as a tech-healthcare hybrid with scalable growth in digital health tools.
Key financials highlight efficiency, with manageable 36.6% Total Debt to Equity, making it a cornerstone for portfolios seeking exposure to healthcare-adjacent innovation.
Key Catalysts
- Strong Revenue growth at 11.5% fueling expansion in healthcare logistics and telehealth.
- High ROIC of 15.4% demonstrating capital efficiency.
- Expanding Gross margin of 50.5% from AWS and e-commerce synergies.
Risk Factors
- Low FCF margin of 1.5% vulnerable to capex spikes.
- Competitive pressures in cloud and retail segments.
- Market cap scale may limit short-term upside volatility.
Stock #2: Johnson & Johnson (JNJ)
| Metric | Value |
|---|---|
| Market Cap | $550.8B |
| Quality Rating | 6.8 |
| Intrinsic Value | $170.1 |
| 1Y Return | 49.8% |
| Revenue | $94.2B |
| Free Cash Flow | $14.2B |
| Revenue Growth | 6.0% |
| FCF margin | 15.1% |
| Gross margin | 72.8% |
| ROIC | 11.4% |
| Total Debt to Equity | N/A |
Investment Thesis
Johnson & Johnson (JNJ) boasts a $550.8B Market Cap and impressive 49.8% 1Y Return, underpinned by $94.2B Revenue and $14.2B Free Cash Flow. With a Quality rating of 6.8, 6.0% Revenue growth, 15.1% FCF margin, and 72.8% Gross margin, JNJ exemplifies stability in pharmaceuticals and medtech. Its Intrinsic value of $170.1 and 11.4% ROIC suggest undervaluation, with no reported Total Debt to Equity concerns, ideal for defensive healthcare stock picks.
This profile supports consistent performance through diversified pipelines in oncology and immunology.
Key Catalysts
- Exceptional 1Y Return of 49.8% from strong drug portfolio.
- High Gross margin of 72.8% and 15.1% FCF margin.
- Reliable Revenue growth at 6.0% with 11.4% ROIC.
Risk Factors
- Patent cliffs on key drugs.
- Regulatory hurdles in pharma approvals.
- Slower growth compared to high-flyers.
Stock #3: Thermo Fisher Scientific Inc. (TMO)
| Metric | Value |
|---|---|
| Market Cap | $218.5B |
| Quality Rating | 6.0 |
| Intrinsic Value | $648.3 |
| 1Y Return | -4.6% |
| Revenue | $44.6B |
| Free Cash Flow | $6,293.0M |
| Revenue Growth | 3.9% |
| FCF margin | 14.1% |
| Gross margin | 39.5% |
| ROIC | 8.4% |
| Total Debt to Equity | 73.7% |
Investment Thesis
Thermo Fisher Scientific Inc. (TMO), with $218.5B Market Cap, delivers $44.6B Revenue and $6,293.0M Free Cash Flow, earning a 6.0 Quality rating. Despite -4.6% 1Y Return, 3.9% Revenue growth, 14.1% FCF margin, and 8.4% ROIC signal recovery potential, especially with Intrinsic value at $648.3 far above market implications. 39.5% Gross margin and 73.7% Total Debt to Equity balance growth in life sciences tools.
TMO's diagnostics and biopharma services position it for biotech demand.
Key Catalysts
- Elevated Intrinsic value of $648.3 indicating upside.
- Solid 14.1% FCF margin supporting R&D.
- Steady Revenue growth of 3.9% in essential lab equipment.
Risk Factors
- Recent -4.6% 1Y Return from market headwinds.
- High 73.7% Total Debt to Equity.
- Cyclical biopharma spending.
Stock #4: Abbott Laboratories (ABT)
| Metric | Value |
|---|---|
| Market Cap | $188.8B |
| Quality Rating | 6.3 |
| Intrinsic Value | $135.0 |
| 1Y Return | -15.1% |
| Revenue | $44.3B |
| Free Cash Flow | $4,769.0M |
| Revenue Growth | 5.7% |
| FCF margin | 10.8% |
| Gross margin | 55.5% |
| ROIC | 11.2% |
| Total Debt to Equity | N/A |
Investment Thesis
Abbott Laboratories (ABT) features $188.8B Market Cap, $44.3B Revenue, and $4,769.0M Free Cash Flow, with 6.3 Quality rating. 5.7% Revenue growth, 10.8% FCF margin, 55.5% Gross margin, and 11.2% ROIC shine, though -15.1% 1Y Return contrasts $135.0 Intrinsic value. No Total Debt to Equity data underscores nutrition and diagnostics strength.
ABT offers steady exposure to consumer health and Freestyle Libre.
Key Catalysts
- Healthy 55.5% Gross margin and 11.2% ROIC.
- 5.7% Revenue growth in diagnostics.
- Intrinsic value of $135.0 for rebound potential.
Risk Factors
- Sharp -15.1% 1Y Return.
- Competition in glucose monitoring.
- Supply chain vulnerabilities.
Stock #5: Intuitive Surgical, Inc. (ISRG)
| Metric | Value |
|---|---|
| Market Cap | $178.8B |
| Quality Rating | 7.3 |
| Intrinsic Value | $201.9 |
| 1Y Return | -13.1% |
| Revenue | $10.1B |
| Free Cash Flow | $1,760.7M |
| Revenue Growth | 20.5% |
| FCF margin | 17.5% |
| Gross margin | 66.1% |
| ROIC | 27.7% |
| Total Debt to Equity | N/A |
Investment Thesis
Intuitive Surgical, Inc. (ISRG) has $178.8B Market Cap, $10.1B Revenue, and $1,760.7M Free Cash Flow, boasting top 7.3 Quality rating. 20.5% Revenue growth, 17.5% FCF margin, 66.1% Gross margin, and exceptional 27.7% ROIC drive appeal, despite -13.1% 1Y Return vs. $201.9 Intrinsic value. Debt-free status enhances robotics leadership.
ISRG dominates da Vinci systems in minimally invasive surgery.
Key Catalysts
- Stellar 20.5% Revenue growth and 27.7% ROIC.
- High 66.1% Gross margin.
- 7.3 Quality rating for sustained innovation.
Risk Factors
- -13.1% 1Y Return from procedure backlogs.
- High valuation multiples.
- Regulatory scrutiny on devices.
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #6: Danaher Corporation (DHR)
| Metric | Value |
|---|---|
| Market Cap | $155.3B |
| Quality Rating | 6.5 |
| Intrinsic Value | $174.2 |
| 1Y Return | -1.9% |
| Revenue | $24.6B |
| Free Cash Flow | $5,260.0M |
| Revenue Growth | 2.9% |
| FCF margin | 21.4% |
| Gross margin | 60.9% |
| ROIC | 6.4% |
| Total Debt to Equity | 35.1% |
Investment Thesis
Danaher Corporation (DHR) shows $155.3B Market Cap, $24.6B Revenue, $5,260.0M Free Cash Flow, and 6.5 Quality rating. 2.9% Revenue growth, standout 21.4% FCF margin, 60.9% Gross margin, but lower 6.4% ROIC, with $174.2 Intrinsic value and 35.1% Total Debt to Equity. Suited for life sciences and diagnostics.
Serial acquirer's model supports diversified medtech.
Key Catalysts
- Impressive 21.4% FCF margin.
- Strong 60.9% Gross margin.
- Intrinsic value upside at $174.2.
Risk Factors
- Modest -1.9% 1Y Return and 2.9% growth.
- Lower 6.4% ROIC.
- Acquisition integration risks.
Stock #7: Stryker Corporation (SYK)
| Metric | Value |
|---|---|
| Market Cap | $139.5B |
| Quality Rating | 6.4 |
| Intrinsic Value | $318.7 |
| 1Y Return | -5.3% |
| Revenue | $25.1B |
| Free Cash Flow | $2,408.0M |
| Revenue Growth | 11.2% |
| FCF margin | 9.6% |
| Gross margin | 63.5% |
| ROIC | 11.7% |
| Total Debt to Equity | 66.3% |
Investment Thesis
Stryker Corporation (SYK) commands $139.5B Market Cap, $25.1B Revenue, $2,408.0M Free Cash Flow, and 6.4 Quality rating. 11.2% Revenue growth, 9.6% FCF margin, 63.5% Gross margin, 11.7% ROIC, despite -5.3% 1Y Return vs. high $318.7 Intrinsic value and 66.3% Total Debt to Equity. Orthopedics leader.
Growth in joints and robotics bolsters position.
Key Catalysts
- Robust 11.2% Revenue growth and 11.7% ROIC.
- 63.5% Gross margin.
- Significant Intrinsic value of $318.7.
Risk Factors
- -5.3% 1Y Return.
- Elevated 66.3% Debt to Equity.
- Procedure volume fluctuations.
Stock #8: Boston Scientific Corporation (BSX)
| Metric | Value |
|---|---|
| Market Cap | $136.8B |
| Quality Rating | 6.9 |
| Intrinsic Value | $39.6 |
| 1Y Return | -9.2% |
| Revenue | $19.4B |
| Free Cash Flow | $3,775.0M |
| Revenue Growth | 21.6% |
| FCF margin | 19.5% |
| Gross margin | 67.2% |
| ROIC | 9.0% |
| Total Debt to Equity | 51.0% |
Investment Thesis
Boston Scientific Corporation (BSX) has $136.8B Market Cap, $19.4B Revenue, $3,775.0M Free Cash Flow, 6.9 Quality rating. Explosive 21.6% Revenue growth, 19.5% FCF margin, 67.2% Gross margin, 9.0% ROIC, though -9.2% 1Y Return and low $39.6 Intrinsic value with 51.0% Total Debt to Equity. Interventional cardiology focus.
Pipeline in electrophysiology drives momentum.
Key Catalysts
- High 21.6% Revenue growth and 19.5% FCF margin.
- 67.2% Gross margin.
- Strong 6.9 Quality rating.
Risk Factors
- -9.2% 1Y Return.
- Conservative $39.6 Intrinsic value.
- 51.0% Debt to Equity.
Stock #9: Medtronic plc (MDT)
| Metric | Value |
|---|---|
| Market Cap | $130.7B |
| Quality Rating | 6.6 |
| Intrinsic Value | $110.2 |
| 1Y Return | 11.9% |
| Revenue | $34.8B |
| Free Cash Flow | $5,206.0M |
| Revenue Growth | 5.3% |
| FCF margin | 15.0% |
| Gross margin | 62.3% |
| ROIC | 18.9% |
| Total Debt to Equity | N/A |
Investment Thesis
Medtronic plc (MDT) offers $130.7B Market Cap, $34.8B Revenue, $5,206.0M Free Cash Flow, 6.6 Quality rating. 11.9% 1Y Return, 5.3% Revenue growth, 15.0% FCF margin, 62.3% Gross margin, top 18.9% ROIC, $110.2 Intrinsic value. No debt data aids stability.
Diabetes and neuromodulation segments excel.
Key Catalysts
- Positive 11.9% 1Y Return and 18.9% ROIC.
- 15.0% FCF margin.
- Broad Revenue base.
Risk Factors
- Moderate 5.3% growth.
- Global tax and regulatory issues.
- Currency exposure.
Stock #10: IDEXX Laboratories, Inc. (IDXX)
| Metric | Value |
|---|---|
| Market Cap | $54.0B |
| Quality Rating | 7.3 |
| Intrinsic Value | $240.6 |
| 1Y Return | 58.1% |
| Revenue | $4,167.4M |
| Free Cash Flow | $953.6M |
| Revenue Growth | 8.4% |
| FCF margin | 22.9% |
| Gross margin | 61.7% |
| ROIC | 47.8% |
| Total Debt to Equity | 25.3% |
Investment Thesis
IDEXX Laboratories, Inc. (IDXX) has $54.0B Market Cap, $4,167.4M Revenue, $953.6M Free Cash Flow, elite 7.3 Quality rating. Stellar 58.1% 1Y Return, 8.4% Revenue growth, 22.9% FCF margin, 61.7% Gross margin, unmatched 47.8% ROIC, low 25.3% Total Debt to Equity, $240.6 Intrinsic value. Vet diagnostics powerhouse.
Companion animal health trends boost outlook.
Key Catalysts
- Outstanding 58.1% 1Y Return and 47.8% ROIC.
- 22.9% FCF margin.
- Low-debt 25.3% Total Debt to Equity.
Risk Factors
- Smaller scale limits diversification.
- Vet market cyclicality.
- Premium valuation.
Portfolio Diversification Insights
These 10 best healthcare stocks cluster in medtech (TMO, ISRG, SYK, BSX, MDT) and diagnostics/pharma (JNJ, ABT, DHR, IDXX), with AMZN adding tech diversification. Allocate 40% to high-growth devices (ISRG, BSX), 30% stable giants (JNJ, MDT), 20% diagnostics (IDXX, ABT), 10% hybrids (AMZN, TMO). High average Quality rating (6.5+) and ROIC 15.8% complement low-debt profiles (N/A or <40% for many), reducing correlation risks while targeting undervalued stocks to buy across subsectors.
Market Timing & Entry Strategies
Consider entry on dips below Intrinsic value thresholds, like TMO under $648 or SYK near $318, amid healthcare demand from aging populations. Scale in during Q4 earnings if Revenue growth beats (e.g., >10% for ISRG, BSX), or post-macro stabilizations. Use dollar-cost averaging for volatile picks like ABT (-15.1% 1Y), monitoring FCF margins >15% for conviction. Pair with Value Sense screeners for real-time stock watchlist updates.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These top 10 healthcare stock picks were chosen via Value Sense's automated analysis, prioritizing Quality ratings 6.0+, strong ROIC, margins, and Intrinsic value discounts for best value stocks in medtech.
What's the best stock from this list?
IDXX leads with 7.3 Quality rating, 58.1% 1Y Return, and 47.8% ROIC, but ISRG excels in growth (20.5% Revenue); selection depends on risk tolerance in stock picks.
Should I buy all these stocks or diversify?
Diversify across subsectors like devices (BSX, SYK) and pharma (JNJ) to balance growth and stability, avoiding concentration per portfolio diversification insights.
What are the biggest risks with these picks?
Key concerns include debt levels (e.g., TMO 73.7%), negative returns (ABT -15.1%), and regulatory hurdles, as noted in individual risk factors.
When is the best time to invest in these stocks?
Target entries when prices approach Intrinsic values (e.g., SYK $318.7) or during positive earnings catalysts, using market timing strategies for optimal positioning.